Advanced Cell Diagnostics Inc. (ACD), a Hayward, CA-based life science research and clinical diagnostics company, has raised $12m in Series B financing.
Backers include New Leaf Venture Partners and Morningside Ventures.
The company intends to use the capital to expand its commercial efforts for its proprietary technology RNAscope®-based products and services into the life science research market and to accelerate the entry of RNAscope into the clinical diagnostics market.
Led by Dr. Yuling Luo, Founder, President and CEO, ACD develops cell- and tissue-based diagnostic tests for personalized medicine. The company’s products and services are based on its proprietary RNAscope® technology, a multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single-molecule sensitivity. ACD partners with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development in cancer and other diseases.
FinSMEs
01/11/2012